Matthew Vander Heiden and Bridge Project collaborators demonstrate in a Nature Cancer paper that metabolic differences between primary and metastatic brain tumors may serve as therapeutic targets. The research team showed that breast cancer metastases in the brain require fatty acid synthase expression because they must make their own fats, as compared to breast cancer tumors in the breast, where fats are abundant and accessible. Therapies that inhibit fatty acid synthase in these brain metastases may be a promising strategy for combatting these fatal and drug resistant tumors. This work was also supported in part by the MIT Center for Precision Cancer Medicine, and the Ludwig Center at MIT.